𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma

✍ Scribed by Michael Wang; Donna M. Weber; Kay Delasalle; Raymond Alexanian

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
59 KB
Volume
79
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The value of thalidomide–dexamethasone was assessed in 26 consecutive, previously untreated patients with multiple myeloma of high tumor mass. All showed Hgb < 8.5 g/dL, serum calcium > 11.5 mg/dL, or both. The response rate was 73%, frequency of early death < 3 months was 5%, projected median survival was 30 months, and projected median remission time was 25 months. There were no occurrences of grade 3 or 4 neutropenia or thrombocytopenia, so that serious infection occurred in only 12% of patients. Thalidomide–dexamethasone was useful for these patients with advanced disease because of the high response rate and acceptable survival, with a low frequency of serious complications. Am. J. Hematol. 79:194–197, 2005. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Total body irradiation (TBI) as primary
Total body irradiation (TBI) as primary therapy for advanced lymphosarcoma
✍ Ralph E. Johnson 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

The natural history of lymphocytic lymphomas is such that diffuse involvement usually is present at diagnosis. Extensive lymphatic irradiation with tumoricidal doses is seldom an appropriate form of treatment, as most patients require systemic therapy. W e have investigated total body irradiation(TB